Dren Bio Closes 350 Million Dollar Financing

Company Dren Bio Event Type Private financing Modality Anti-CD94 antibody (cytotoxic-cell depletion) Asset Dibotatug (DR-01) Target CD94 Disease Area Cytotoxic T-cell lymphoma; large granular lymphocytic leukemia Summary Dren Bio announced an oversubscribed $350 million private financing on 29 October to advance CD94 antibody dibotatug through…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

Astellas / AviadoBio – Gene Therapy Program Sustained via Nonprofit Funding
Samsung Biologics Moves Into Peptide Manufacturing
Boulevard Bio Launches with $65 Million
GSK Acquires a Preclinical Trispecific Myeloma TCE